Evaluate the expected performance of Gilead (GILD) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be a significant boost. We recommend investors to wait and watch for now.
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.25, denoting a +2% change from the preceding trading day.
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Gilead Sciences (GILD) reachead $112.39 at the closing of the latest trading day, reflecting a +0.45% change compared to its last close.
In the most recent trading session, Gilead Sciences (GILD) closed at $111.88, indicating a +0.54% shift from the previous trading day.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.